Jennison Associates
VERA icon

Jennison Associates’s Vera Therapeutics VERA Stock Holding History

Jennison Associates’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-507,838
Closed -$12.2M – 634
2025
Q1 		$12.2M Sell
507,838
-306,023
-38% -$9.83M 0.01% 371
2024
Q4 		$34.4M Buy
813,861
+366,763
+82% +$16.2M 0.02% 277
2024
Q3 		$19.8M Buy
447,098
+5,936
+1% +$225K 0.01% 343
2024
Q2 		$16M Buy
441,162
+366,223
+489% +$14.5M 0.01% 347
2024
Q1 		$3.23M Buy
+74,939
New +$2.67M ﹤0.01% 446

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jennison Associates's VERA Position: Q2 2025 in Review

Jennison Associates sold out of Vera Therapeutics (VERA) in Q2 2025, closing a stake of 507,838 shares — an estimated $12.2M sold.

Jennison Associates first reported a position in VERA in Q1 2024 and held it in 5 quarters. The position peaked at $34.4M in Q4 2024. 172 funds tracked by Wall St. Rank hold VERA as of Q2 2025.

  • Jennison Associates reported no remaining Vera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 507,838 Vera Therapeutics shares in Q2 2025, an estimated $12.2M.
  • Jennison Associates first reported a position in Vera Therapeutics in Q1 2024 and held it in 5 quarters.
  • Jennison Associates's Vera Therapeutics position peaked at $34.4M in Q4 2024.
  • 172 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.